Allergan near buyout of up to $65 billion to escape Valeant, Ackman: source

[admin]

(Reuters) - Allergan Inc is close to a buyout deal worth up to $65.5 billion by Actavis Plc, one that could end months of pursuit by Canada’s Valeant Pharmaceuticals and William Ackman's hedge fund, Pershing Square Capital Management, according to a person familiar with the matter.



More...